◆英語タイトル:Second Genome Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10587
◆発行会社(調査会社):
GlobalData
◆発行日:2018年11月
◆ページ数:27
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Second Genome Inc (Second Genome), formerly PhyloTech Inc, is a clinical stage pharmaceutical company that provides microbial research and drug discovery services. The company’s pipeline products include SGM-1019, a small molecule inhibitor targeting tissue injury and inflammation; and SG-2-0776, a therapeutic protein, which repairs damage caused to the intestinal epithelium. The company discovers, tests and validates product candidates through host-microbe interaction. It harnesses the proprietary microbiome drug discovery platform to develop novel medicines for a range of diseases including liver diseases, inflammatory bowel disease, metabolic diseases, immuno-oncology and central nervous system disorders. The company works in collaboration with other organizations to discover and develop microbiome-modulating medicines. Second Genome is headquartered in South San Francisco, California, the US.
Second Genome Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Second Genome Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Second Genome Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Second Genome Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Second Genome Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Second Genome Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Second Genome Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Second Genome Raises USD8.4 Million in Extended Series B Financing 11
Second Genome Raises USD42.6 Million in Series B Financing 12
Second Genome Raises US$6.5 Million In Extended Series A Financing 14
Partnerships 15
Second Genome Enters into Research Partnership with John Theurer Cancer Center 15
Second Genome Enters into Research Partnership with Stanford Cancer Institute, Ruprecht-Karls University Heidelberg and Roswell Park Cancer Comprehensive Cancer Center 16
Second Genome Enters into Research Partnership with Roswell Park Cancer Comprehensive Cancer Center and John Theurer Cancer Center 17
Second Genome Enters into Research Agreement with APC 18
Second Genome Enters into Agreement with Evotec 19
Second Genome Enters into Co-Development Agreement with Mayo Clinic Center for Individualized Medicine 20
Second Genome Enters Into Agreement With Janssen Biotech For Microbiome Drug Discovery 21
Second Genome Inc – Key Competitors 22
Second Genome Inc – Key Employees 23
Second Genome Inc – Locations And Subsidiaries 24
Head Office 24
Recent Developments 25
Corporate Communications 25
Sep 26, 2018: Second Genome Appoints Karim Dabbagh, Ph.D., as Chief Executive Officer 25
Government and Public Interest 26
Oct 03, 2017: Second Genome Launches Study of the Relationship Between Microbiome and Central Nervous System in Autism Spectrum Disorders 26
Appendix 27
Methodology 27
About GlobalData 27
Contact Us 27
Disclaimer 27
List of Tables
Second Genome Inc, Pharmaceuticals & Healthcare, Key Facts 2
Second Genome Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Second Genome Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Second Genome Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Second Genome Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Second Genome Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Second Genome Raises USD8.4 Million in Extended Series B Financing 11
Second Genome Raises USD42.6 Million in Series B Financing 12
Second Genome Raises US$6.5 Million In Extended Series A Financing 14
Second Genome Enters into Research Partnership with John Theurer Cancer Center 15
Second Genome Enters into Research Partnership with Stanford Cancer Institute, Ruprecht-Karls University Heidelberg and Roswell Park Cancer Comprehensive Cancer Center 16
Second Genome Enters into Research Partnership with Roswell Park Cancer Comprehensive Cancer Center and John Theurer Cancer Center 17
Second Genome Enters into Research Agreement with APC 18
Second Genome Enters into Agreement with Evotec 19
Second Genome Enters into Co-Development Agreement with Mayo Clinic Center for Individualized Medicine 20
Second Genome Enters Into Agreement With Janssen Biotech For Microbiome Drug Discovery 21
Second Genome Inc, Key Competitors 22
Second Genome Inc, Key Employees 23
List of Figures
Second Genome Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Second Genome Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Second Genome Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Second Genome Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Second Genome Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Second Genome Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Second Genome Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Second Genome Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8